What is the recommended acute management and prophylactic treatment for supraventricular tachycardia?

Management of Supraventricular Tachycardia

For acute SVT management, start with vagal maneuvers immediately, followed by intravenous adenosine if unsuccessful, and proceed to synchronized cardioversion for hemodynamically unstable patients or those who fail pharmacologic therapy. 1

Acute Management Algorithm

Step 1: Assess Hemodynamic Stability

Determine if the patient has hypotension, altered mental status, chest pain suggesting ischemia, or signs of heart failure. If hemodynamically unstable, proceed directly to synchronized cardioversion 1.

Step 2: Hemodynamically Stable Patients

First-Line: Vagal Maneuvers 1

• Valsalva maneuver: Patient bears down against closed glottis for 10-30 seconds (equivalent to 30-40 mm Hg intrathoracic pressure) in supine position
• Carotid sinus massage: After confirming absence of bruit, apply steady pressure over right or left carotid sinus for 5-10 seconds
• Diving reflex: Apply ice-cold wet towel to face (particularly effective in infants)
• Success rate: 27.7% when switching between techniques
• Critical caveat: Never apply pressure to eyeballs—this is dangerous and abandoned

Second-Line: Intravenous Adenosine 1

• Effectiveness: Terminates AVNRT in ~95% of patients and orthodromic AVRT in 90-95% 1
• Administration: Rapid IV bolus
• Side effects: Minor and brief (<1 minute) in ~30% of patients
• Critical warning: Have cardioversion immediately available—adenosine may precipitate atrial fibrillation that conducts rapidly to ventricles, potentially causing ventricular fibrillation 1

Third-Line: IV Calcium Channel Blockers or Beta-Blockers 1

• IV diltiazem or verapamil: Particularly effective for AVNRT conversion (80-98% success rate)
• IV beta-blockers: Reasonable alternative with excellent safety profile, though less effective than diltiazem
• Contraindications:
  • Do NOT use in suspected ventricular tachycardia or pre-excited atrial fibrillation (risk of ventricular fibrillation)
  • Avoid in systolic heart failure
  • Use cautiously in patients with pre-excitation on resting ECG (may enhance accessory pathway conduction) 1

Fourth-Line: Synchronized Cardioversion 1

• Indicated when pharmacologic therapy fails or is contraindicated
• Perform after adequate sedation/anesthesia in stable patients
• Highly effective for terminating all forms of SVT

Step 3: Hemodynamically Unstable Patients

Immediate synchronized cardioversion 1

• Do not delay for vagal maneuvers or medications
• Particularly critical in pre-excited atrial fibrillation (risk of ventricular fibrillation)

Special Consideration: Pre-Excited Atrial Fibrillation

This is a distinct and dangerous entity requiring different management 1:

Hemodynamically unstable: Immediate synchronized cardioversion 1

Hemodynamically stable: IV ibutilide or procainamide 1

• These agents slow accessory pathway conduction and may terminate AF
• Never use AV nodal blockers (diltiazem, verapamil, beta-blockers, digoxin) as they may enhance accessory pathway conduction, leading to ventricular fibrillation

Prophylactic/Ongoing Management

First-Line: Catheter Ablation

Catheter ablation is the definitive treatment and should be offered as first-line therapy for recurrent symptomatic SVT 2, 3

• Single procedure success rates: 94.3-98.5% 2
• Very low risk of AV block for AVNRT ablation
• Preferred over long-term pharmacotherapy given superior efficacy and avoidance of medication side effects

Pharmacologic Prophylaxis (for patients declining or not candidates for ablation)

For AVNRT: 1

• Oral verapamil or diltiazem: First-line pharmacologic option
• Oral beta-blockers: Alternative with excellent safety profile
• Monitor for bradyarrhythmias and hypotension
• Avoid in systolic heart failure

For AVRT with pre-excitation:

• Avoid digoxin (may shorten accessory pathway refractory period)
• Beta-blockers are safer first choice
• Class Ic agents (flecainide, propafenone) or sotalol as next steps 4

"Pill-in-the-Pocket" Strategy 5, 6

• Combination of oral diltiazem and propranolol for patient self-administration
• Success rate: 81-94% for terminating episodes within 2 hours 5
• Reduces emergency room visits by 91% 5
• Important limitation: Delayed onset of action (32-74 minutes) and risk of hypotension/bradycardia
• Note: The 2019 ESC guidelines downgraded this approach 7, and newer evidence suggests limited robust support 6

Critical Pitfalls to Avoid

1. Never use IV verapamil in infants <1 year old (risk of cardiovascular collapse) 8, 4
2. Never give AV nodal blockers in wide-complex tachycardia until ventricular tachycardia is excluded 1
3. Never give AV nodal blockers in pre-excited AF (may precipitate ventricular fibrillation) 1
4. Always have cardioversion available when administering adenosine 1
5. Avoid digoxin and amiodarone for acute narrow-complex SVT (downgraded/no longer recommended) 7

Recent Guideline Changes

The 2019 ESC guidelines 7 made significant changes from prior recommendations:

• Upgraded: Adenosine for wide-QRS tachycardias; beta-blockers for narrow-QRS and AVRT
• Downgraded: Verapamil/diltiazem for acute narrow-QRS; procainamide and amiodarone for wide-QRS
• No longer recommended: Amiodarone and digoxin for acute narrow-QRS; sotalol for various indications; "pill-in-the-pocket" for AVNRT/AVRT

The 2015 ACC/AHA/HRS guidelines [1-9] remain the most comprehensive North American resource and align with the algorithmic approach outlined above.